Trials / Completed
CompletedNCT01142661
Compassionate Use of Eribulin for the Treatment of Advanced Breast Cancer Refractory to All Other Marketed Therapies
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 9 (actual)
- Sponsor
- Eisai Inc. · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to provide eribulin to patients with advanced breast cancer who have no other treatment options and therapy is requested by an Investigator.
Detailed description
This compassionate use program will consist of a Pretreatment Phase and a Treatment Phase. Patients with locally advanced or metastatic breast cancer who fulfill the eligibility criteria may be treated. Safety data will be collected, but a minimal amount of other data will also be collected.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Eribulin Mesylate | Eribulin Mesylate: A dose of 1.4 mg/m\^2 given intravenously on Day 1 and Day 8 of a 21 day cycle, continued until disease progression, unacceptable toxicity or death. |
Timeline
- Start date
- 2010-08-01
- Primary completion
- 2011-08-01
- First posted
- 2010-06-11
- Last updated
- 2013-09-20
- Results posted
- 2013-09-20
Locations
5 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01142661. Inclusion in this directory is not an endorsement.